TransMedics Group Inc. (NASDAQ:TMDX) reported insider transactions by Chief Financial Officer Gerardo Hernandez in a Form 4 filing with the Securities and Exchange Commission detailing share sales on March 2 and March 4.
On March 2, Hernandez sold 375 shares of common stock at $139.12 apiece. Two days later, on March 4, he sold 7,236 shares at a weighted average price of $147.21, with execution prices on that date ranging from $147.14 to $147.47. Together, those sales total approximately $1.12 million.
The March 4 activity also included Hernandez exercising options to acquire 7,236 shares of TransMedics Group common stock. The option strike prices that were exercised ranged from $69.84 to $77.12, and the aggregate cost to exercise those options was $515,000.
After recording the option exercises and the subsequent sales, Hernandez is reported to directly own 14,689 shares of TransMedics Group.
These insider moves come as TransMedics shares trade close to a 52-week high of $156 and following a strong run for the stock, which has returned 119% over the past year.
Separately, the company announced fourth-quarter 2025 financial results that exceeded analyst estimates across key metrics. Adjusted earnings per share for the quarter were $2.62, well ahead of the consensus estimate of $0.39. Revenue in the period reached $160.8 million versus an analyst estimate of $155.98 million, representing a 32% increase from the prior year's quarter, which recorded $121.6 million in revenue.
TransMedics also issued full-year 2026 revenue guidance of $727 million to $757 million, which implies year-over-year growth of approximately 20% to 25%. The midpoint of that range - $742 million - is slightly above the analyst consensus of $725 million referenced in the company announcement.
The company disclosed a $103.3 million release of a U.S. tax valuation allowance, which affected fourth-quarter results by producing an $83.8 million net income tax benefit in the period.
Following the quarter and related disclosures, Needham revised its price target on TransMedics stock to $174 from $166 and retained a Buy rating on the shares.
Operationally, TransMedics completed 5,139 U.S. OCS cases in 2025, a 38% increase compared with the prior year, a figure the company highlighted alongside its financial results.
The transactions and company disclosures together present a snapshot of both insider activity and company performance: a senior executive's option exercise and partial disposition of shares occurring in close proximity to stronger-than-expected quarterly results and an upward revenue outlook for the coming year.
Readers should note the facts above are drawn from the company's SEC filing and its reported quarterly results and guidance.